<DOC>
	<DOC>NCT00493766</DOC>
	<brief_summary>This is a parallel, two-arm, open-label, multicenter phase IA/IB study of LBH589 (oral formulation) alone and in combination with docetaxel in patients with progressing hormone refractory prostate cancer. This study is designed to determine the maximum tolerated dose of LBH589 as a single agent and in combination with docetaxel and prednisone 5 mg two times a day , and to characterize the safety, tolerability, biologic activity and pharmacokinetic profile</brief_summary>
	<brief_title>Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Inclusion criteria: Histologically documented adenocarcinoma of the prostate. Patients must have metastatic disease with at least one measurable soft tissue lesion that can be assessed by computerized tomography (CT), or magnetic resonance imaging (MRI) and/or detectable lesion(s) on bone scintigraphy scan. Patients with only elevated prostate specific antegen (PSA) levels are not eligible for entry. Patients who have undergone medical castration must continue Luteinizing hormonereleasing hormone (LHRH) agonist or antagonist therapy during study treatment Patients must be able to provide written informed consent Exclusion criteria: Patients with prior or concurrent brain metastases Impaired cardiac, gastrointestinal, kidney, or liver function Use of therapeutic androgens Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>LBH589</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>HRPC</keyword>
	<keyword>Hormone Refractory Prostate Cancer</keyword>
</DOC>